39L Stock Overview
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PetIQ, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.20 |
| 52 Week High | US$21.20 |
| 52 Week Low | US$10.20 |
| Beta | 1.67 |
| 1 Month Change | -5.00% |
| 3 Month Change | -8.98% |
| 1 Year Change | 44.76% |
| 3 Year Change | -59.14% |
| 5 Year Change | -45.11% |
| Change since IPO | -23.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 39L | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -1.9% | 3.7% | -2.0% |
| 1Y | 44.8% | -3.9% | -0.3% |
Return vs Industry: 39L exceeded the German Healthcare industry which returned -3.9% over the past year.
Return vs Market: 39L exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| 39L volatility | |
|---|---|
| 39L Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 39L has not had significant price volatility in the past 3 months.
Volatility Over Time: 39L's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,527 | Cord Christensen | petiq.com |
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
PetIQ, Inc. Fundamentals Summary
| 39L fundamental statistics | |
|---|---|
| Market cap | €454.15m |
| Earnings (TTM) | €2.00m |
| Revenue (TTM) | €1.03b |
228.4x
P/E Ratio0.4x
P/S RatioIs 39L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 39L income statement (TTM) | |
|---|---|
| Revenue | US$1.10b |
| Cost of Revenue | US$849.22m |
| Gross Profit | US$252.74m |
| Other Expenses | US$250.61m |
| Earnings | US$2.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 0.072 |
| Gross Margin | 22.94% |
| Net Profit Margin | 0.19% |
| Debt/Equity Ratio | 199.7% |
How did 39L perform over the long term?
See historical performance and comparison